CHP-NY-ESO-1, MIS416

2 trials

Sponsors

Mie University Graduate School of Medicine

Conditions

Refractory Solid TumorRefractory Urothelial or Prostate Cancer

Phase 1

Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate Cancer

Active, not recruitingJPRN-UMIN000005246

Mie University Graduate School of MedicineRefractory Urothelial or Prostate Cancer

Start: 2011-03-01Target: 12Updated: 2026-06-29

Phase I Clinical Study on the Long-term Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1-expressing Refractory Solid tumor.

Active, not recruitingJPRN-UMIN000008006

Mie University Graduate School of MedicineRefractory Solid Tumor

Start: 2012-05-01Target: 24Updated: 2026-06-29

Related Papers

First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors.

Journal of Clinical Oncology2018-05-201 citations